APP inhibitors(Beta amyloid A4 protein inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), LOXL2 inhibitors(Lysyl oxidase homolog 2 inhibitors)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [8]

Active Indication

RadiodermatitisHepatocellular CarcinomaLiver Cirrhosis+ [9]

Inactive Indication

Alzheimer DiseaseBrain atrophyHuntington Disease+ [2]

Originator Organization

Charité - Universitätsmedizin Berlin

Active Organization

The University of Texas Southwestern Medical Center

Universidad de Guanajuato

Nanchang University

+ [7]

Inactive Organization

Charité - Universitätsmedizin Berlin

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC22H18O11

InChIKeyWMBWREPUVVBILR-WIYYLYMNSA-N

CAS Registry989-51-5

Clinical Trials associated with (-)-Epigallocatechin Gallate

NCT07578311

/ Not yet recruitingNot ApplicableIIT

Effect Of Phytotherapeutics As Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment. (Randomized Clinical Trial)

The primary objective of this randomized clinical trial is to evaluate and compare the effectiveness of two natural, herbal-based intracanal medications-Propolis and Green Tea Polyphenolics (EGCG)-against the conventional Calcium Hydroxide in reducing postoperative pain and the incidence of flare-ups during non-surgical root canal retreatment.
Postoperative pain is a common complication in endodontics, particularly in retreatment cases where complex bacterial environments and procedural challenges increase the risk of discomfort and acute flare-ups. While Calcium Hydroxide is the traditional gold standard due to its antimicrobial properties, natural phytotherapeutics like Propolis and Green Tea are being investigated for their potent anti-inflammatory, antioxidant, and antibacterial benefits, which may offer superior biocompatibility and symptomatic relief.
Forty patients requiring endodontic retreatment of single-rooted teeth will be randomly assigned to one of three groups:
Group I (Control): Receives Calcium Hydroxide paste.
Group II: Receives Propolis-based medication.
Group III: Receives Green Tea Polyphenolic-based medication.
The study follows a two-visit protocol. During the first visit, the previous root canal filling is removed, the canal is cleaned and shaped, and the assigned medication is placed. Postoperative pain will be assessed using a Visual Analog Scale (VAS) at 6, 12, 24, 48, 72 hours, and 7 days. Flare-up incidence (sudden severe pain or swelling) will also be monitored. In the second visit, the medication is removed, and the canal is permanently sealed using a bioceramic sealer and gutta-percha. The results will help determine if these herbal alternatives can provide a more comfortable treatment experience for patients undergoing root canal retreatment.

Start Date01 Jul 2026

Sponsor / Collaborator

Minia University

NCT07572396

/ RecruitingPhase 2

A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology

The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerability of this investigational therapy. The main questions it aims to answer are:
* Does the investigational therapy lead to regression of cervical lesions?
* Does the investigational therapy help clear hr-HPV infection?
* Do any adverse effects occur from using this medical product?
Researchers will compare the investigational therapy to a placebo (a look-alike substance that contains no active drug) to see if the investigational therapy works.
Participants will:
* Be screened for hr-HPV, cervical abnormalities, and other conditions to be assessed for eligibility
* Self-administer 15 doses of the investigational therapy or placebo as a vaginal suppository over 19 calendar days
* Attend scheduled clinic visits for examinations, testing, and monitoring for a period of two months
* Undergo assessments to evaluate cervical lesion status, hr-HPV infection, and safety outcomes
* Keep a daily diary of investigational therapy use and associated information

Start Date30 Apr 2026

Sponsor / Collaborator

Amplexd Therapeutics, Inc.

[+1]

JPRN-UMIN000059245

/ RecruitingNot Applicable

Examination of the effects of consuming a food containing lactic acid bacteria WB21 and epigallocatechin gallate (Avantbise Oral Tablets) on gingival condition and microorganisms in tongue coating

Start Date16 Sep 2025

Sponsor / Collaborator

Fukuoka Dental College

100 Clinical Results associated with (-)-Epigallocatechin Gallate

100 Translational Medicine associated with (-)-Epigallocatechin Gallate

100 Patents (Medical) associated with (-)-Epigallocatechin Gallate

11,934

Literatures (Medical) associated with (-)-Epigallocatechin Gallate

31 Dec 2026·ANNALS OF MEDICINE

Epigenetic regulators polyphenols in neurodegenerative diseases: a promising intervention strategy

Review

Author: Li, Lu-Hao ; Han, De-xiong ; Wang, Jia-qi ; He, Ke-lin ; Chang, Zhuo ; Wu, Lei ; Wang, Xiao-xiang ; Huang, Yi ; Xu, Cheng-cheng ; Ma, Rui-jie

BACKGROUND:

Neurodegenerative diseases are complex disorders characterized by the progressive loss of neuronal structure and function, involving pathological mechanisms such as oxidative stress, chronic inflammation, protein misfolding, and impaired synaptic plasticity. Recent studies have revealed that epigenetic regulation plays a critical role in the onset and progression of these diseases, including mechanisms such as DNA methylation, histone modifications, and non-coding RNA regulation. Natural polyphenolic compounds, known for their safety and multi-target properties, have emerged as promising candidates for neuroprotection and therapeutic intervention.

METHODS:

This review summarizes recent advances in the neuroprotective effects of polyphenols in neurodegenerative diseases through epigenetic mechanisms. It focuses on their regulation of DNA methyltransferase activity, histone acetylation status, and non-coding RNA expression, as well as their influence on neurotrophic factors, inflammatory mediators, and synapse-related gene expression.

RESULTS:

Polyphenolic compounds such as curcumin, resveratrol, and epigallocatechin gallate (EGCG) have been shown to modulate epigenetic enzyme activity, alleviate neuroinflammation, improve mitochondrial function, and promote neuroregeneration, demonstrating multi-level neuroprotective effects. However, clinical translation is limited by low oral bioavailability, rapid metabolism, and insufficient brain-targeting capacity. Emerging strategies including nano-delivery systems, prodrug design, and omics technologies hold promise in overcoming these limitations and enhancing therapeutic efficacy.

CONCLUSIONS:

Polyphenols exert multi-target regulatory effects via epigenetic mechanisms in neurodegenerative diseases, showing great potential for intervention. In the future, integrating precision nutrition, personalized treatment, and multi-omics approaches may facilitate the development of novel epigenetic-based strategies for the prevention and treatment of neurodegenerative disorders.

31 Dec 2026·REDOX REPORT

EGCG-loaded nanoparticles attenuate post-SAH white matter injury by targeting HO-1/S100A10 to suppress oxidative stress-induced reactive astrocytes.

Article

Author: Zheng, Yanning ; Xue, Jiangyu ; Li, Zheng ; Niu, Mengyu ; Chen, Ying ; Zhang, Jing ; Huang, Liyong ; Lang, Dongcen ; Wang, Jian ; Wang, Xue ; Li, Li

OBJECTIVE:

Subarachnoid hemorrhage (SAH) is associated with high mortality and poor outcomes, which are closely related to white matter injury (WMI). (-)-Epigallocatechin-3-gallate (EGCG) exerts neuroprotective effects by inhibiting oxidative stress-related ferroptosis in astrocytes and improving neurological function. However, the role and mechanism of EGCG in regulating reactive astrocytes (RAs) to alleviate WMI after SAH remain unclear.

METHODS:

A mouse model of SAH was used to evaluate the effects of EGCG-loaded nanoparticles (EGCG-NPs). Western blot, qPCR, and immunofluorescence were performed for biochemical analysis. Neurological function was assessed using neurological deficit scores and the Morris water maze test.

RESULTS:

Following SAH, HO-1-mediated iron accumulation and ROS production promoted A1/A2 reactive astrocyte polarization, resulting in myelination damage and aggravated WMI. Knockdown of S100A10 inhibited iron-dependent oxidative stress in RAs and attenuated WMI. EGCG-NPs significantly suppressed HO-1/S100A10-mediated iron overload and oxidative stress in both A1 and A2 RAs, thereby alleviating WMI after SAH.

CONCLUSION:

EGCG-NPs attenuate SAH-induced WMI by inhibiting the iron overload-activated HO-1/S100A10 axis in RAs, representing a promising therapeutic strategy.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Silencing of a carboxylesterase gene NleFE4 in Indian brown planthopper biotype negatively impacts its performance and survival on rice

Article

Author: Ravindranath, Nihal ; Nag, Swapna Rani ; Nanda, Satyabrata ; Sahu, Satya Narayan ; Nayak, Ashutosh ; Gaikwad, Dinakar

BACKGROUND: Rice productivity is severely challenged by the brown planthopper (Nilaparvata lugens Stål, BPH) infestations. Four different biotypes and multiple virulent BPH populations make the pest control even more challenging. Among these biotypes, the biotype 4 found in the Indian sub-continent is considered to be the most destructive. However, the molecular mechanisms of the BPH biotype 4 and rice interactions are explored to a limited extent. METHODS: In this study, the function of a carboxylesterase gene (NleFE4) in the BPH biotype 4 has been investigated via RNA intereference-mediated gene silencing during compatible (BPH fed on TN1 rice) and incompatible (BPH fed on PTB33 rice) rice-BPH interactions. In addition, the NleFE4 silencing effects on the BPH performance and survival were evaluated. Finally, interactions between NleFE4 and key rice secondary metabolites (sakuranetin, phenylpropane, epigallocatechin, spermidine, and quercetin) were predicted. RESULTS: Administration of dsNleFE4 significantly reduced the NleFE4 expression in the BPH. The honeydew amount, BPH weight gain, and BPH survival assays suggested that silencing of NleFE4 negatively affected the BPH performance and survival. The molecular docking analysis results suggested that NleFE4 could interact with all five rice secondary metabolites with varied levels of binding affinities and could be involved in the detoxification of these metabolites during rice-BPH interactions. CONCLUSION: Silencing of NleFE4 had detrimental effects on the BPH performance and survival. NleFE4 could be involved in the detoxification of key rice allelochemicals.

News (Medical) associated with (-)-Epigallocatechin Gallate

21 May 2026

·www.einpresswire.com

Comprehensive Review Catalogues 136 Human Clinical Studies on Sulforaphane and Broccoli Bioactives

Compendium Highlights Broad Use of TrueBroc® in Clinical Studies This body of work reflects the remarkable evolution of sulforaphane research over the past 30 years.” — Dr. Jed Fahey BALTIMORE, MD, UNITED STATES, May 21, 2026 / EINPresswire.com / -- A newly published peer-reviewed paper in Medicines examines the expanding body of research on sulforaphane — the bioactive compound derived from broccoli , broccoli seeds and sprouts, and cruciferous vegetables — highlighting its synergistic interactions with phytochemicals and pharmaceuticals across a wide range of health applications. The publication, “Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan,” was authored by Dr. Jed W. Fahey and Dr. Hua Liu of Johns Hopkins School of Medicine and published on May 6, 2026. Accompanying the paper is a detailed supplemental compendium cataloging 136 human clinical studies using glucoraphanin, sulforaphane, broccoli sprouts, broccoli seed extract(s), or related interventions — spanning metabolic health, cognitive health, inflammation modulation, cardiovascular function, aging, detoxification, autism spectrum disorder, schizophrenia, oncology, and bioavailability research. The supplemental table documents three decades of clinical investigation dating back to 1998 and is updated as of March 15, 2026, to include the most recent activity. “This body of work reflects the remarkable evolution of sulforaphane research over the past 30 years,” said Jed W. Fahey, ScD. “What began as foundational cancer chemoprotection research has expanded into a much broader exploration of oxidative stress, inflammation, epigenetics, detoxification, and cellular resilience.” The review highlights multiple strands of evidence suggesting that sulforaphane may act synergistically with phytochemicals, including EGCG, curcumin, selenium, and quercetin, as well as chemotherapy agents, targeted therapies, and immunotherapies. Across multiple models, researchers observed positive effects on Nrf2-mediated cytoprotective and glutathione-related pathways, apoptosis, modulation of inflammation, oxidative stress response, epigenetic regulation, and cancer stem cell signaling. The publication also underscores the importance of understanding the specifics of interventions to ensure they deliver appropriate quality and dosage, as well as the bioavailability of sulforaphane, given sulforaphane’s significant instability. Many of these studies utilized the TrueBroc ® family of ingredients, which are commercially available sulforaphane-related ingredients used in nutritional supplements. Notably, internal analysis of the subset of clinical studies utilizing commercially available preparations (rather than laboratory-developed or pre-commercial materials) indicates that approximately 79% of the broccoli seed and sprout interventions utilized the TrueBroc ® family of ingredients. The review is dedicated to the memory of Professor Thomas W. Kensler (1948–2025), whose pioneering contributions helped shape the modern understanding of the beneficial properties of sulforaphane and broccoli. TrueBroc ® encompasses a family of broccoli seed-focused ingredients developed to support clinically informed formulation and enhanced sulforaphane bioavailability, building upon decades of foundational research advanced by pioneering scientists, including Dr. Jed Fahey and the late Dr. Paul Talalay. The emerging synergy data further underscores sulforaphane’s potential as a multi-pathway compound with growing relevance to next-generation therapeutic and nutritional strategies. Publication: Fahey JW, Liu H. (2026). Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan. Medicines. 13(2):16. https://www.mdpi.com/2305-6320/13/2/16 M. Raphaely Brassica Protection Products +1 410-732-1200 email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

19 May 2026

·www.biospace.com

Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy

GAITHERSBURG, Md., May 19, 2026 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd”), a U.S.-based clinical-stage biotechnology company focused on women’s health and underserved therapeutic areas, today announced authorization from the Hong Kong Department of Health to initiate a Phase 2 clinical trial evaluating its novel EGCg-based investigational therapy for precancerous cervical lesions associated with high-risk human papillomavirus (hr-HPV). High-risk HPV is the primary driver of cervical cancer, which remains a significant public health burden in the US and around the globe. The randomized, placebo-controlled Phase 2 study is being conducted at The Chinese University of Hong Kong in collaboration with Prince of Wales Hospital, with recruitment currently underway. The study will evaluate the safety and efficacy of Amplexd’s investigational therapy in women diagnosed with ASC-US and low-grade squamous intraepithelial lesions (LSIL) alongside confirmed hr-HPV infection. Clinical data are expected in Q1 2027. The investigational therapy is a proprietary formulation containing epigallocatechin gallate (EGCg), developed as a vaginal suppository for self-administration at the site of disease. “In the US, roughly 5% of cervical screenings reveal abnormalities 1 , the majority of which are low-grade,” said Alia Rahman, Chief Executive Officer of Amplexd. “These lesions are typically managed through increased surveillance known as ‘watchful waiting’ rather than active treatment, while advanced disease stages often require surgical interventions that are not uniformly accessible across healthcare settings. Despite the meaningful psychosocial and financial burdens associated with this approach, therapeutic advancements have been limited, and a significant unmet medical need for localized, non-surgical therapies remains. Previously published, peer-reviewed clinical and preclinical studies have explored the use of EGCg-based topical formulations in the treatment of HPV and cervical lesions. Building on this body of research, we developed a shelf-stable formulation designed for self-administration and early therapeutic intervention.” The Phase 2 trial will evaluate endpoints including lesion regression, viral clearance, and overall safety profile, with the goal of generating data on the potential for early therapeutic intervention in hr-HPV-associated disease. Additional information about the study can be found at under trial identifier NCT07572396. Important Information This clinical trial has been authorized by the Hong Kong Department of Health. Participation will be subject to eligibility criteria and informed consent. This investigational therapy has not been approved by the U.S. Food and Drug Administration, and its safety and efficacy have not been established. About Amplexd Therapeutics, Inc. Amplexd Therapeutics, Inc. is a biotechnology company pioneering science-driven therapies for women’s health and related diseases with high unmet need. Its pipeline leverages novel mechanisms and accessible delivery modalities to expand treatment options for patients. Forward-Looking Statements This press release contains forward-looking statements regarding clinical development plans and potential benefits of the investigational therapy. These statements involve risks and uncertainties that could cause actual results to differ materially. Amplexd Therapeutics, Inc. undertakes no obligation to update these statements except as required by law. Media and Investor Contact: Media Relations press@amplexd.com Investor Relations invest@amplexd.com Amplexd Therapeutics, Inc. _________________________________ 1 Evans KK, Tambouret RH, Evered A, Wilbur DC, Wolfe JM. Prevalence of abnormalities influences cytologists’ error rates in screening for cervical cancer. Arch Pathol Lab Med. 2011 Dec;135(12):1557-60. doi: 10.5858/arpa.2010-0739-OA. PMID: 22129183; PMCID: PMC3966132.

25 Jun 2025

·www.einpresswire.com

Altin Biosciences announces US patent approval for its first-in-class, non-hormonal, oral botanical drug candidate.

A non-surgical, non-hormonal drug that is easy to take, easy to tolerate, and preserves fertility is exactly what patients and doctors have demanded for years. Altin's drug candidate is a significant advancement to offer fibroid patients non-hormonal treatment options that go beyond merely addressing symptoms, offering a paradigm shift in fibroid treatment.” — Ayman Al-Hendy, M.D., Ph.D.,FACOG, University of Chicago EMERYVILLE, CA, UNITED STATES, June 25, 2025 / EINPresswire.com / -- Non-hormonal oral botanical uterine fibroid drug candidate receives USPTO patent approval. Altin Biosciences, a woman-founded botanical drug development company, is pleased to announce the USPTO has granted a Notice of Allowance for a Composition of Matter patent for its lead drug candidate, a non-hormonal, oral treatment for uterine fibroids. US Patent Application No. 18/115,690, titled CRILA ® AND EGCG COMPOSITIONS FOR TREATMENT OF FIBROIDS, protects Altin’s lead drug candidate, ABC-105/ABC-205. Founder and CEO, Sue McKinney, states, “ Altin's fibroid candidate meets the stated ideal for patients and doctors : easy to take, easy to tolerate, preserves fertility, and no hormones. Beyond symptomatic management, we aim to reduce or eliminate the tumors themselves. Altin’s plant-based formula, being developed under the FDA Botanical Drug Guidance, positions Altin for licensing agreements and partnership development for this novel approach to fibroid treatment. We’re pursuing FDA fast track status to meet this urgent need.” Pre-clinical studies utilizing the combination of natural compounds Crinum latifolium L var. crilae Tram & Khanh (Crila ® ) and epigallocatechin gallate (EGCG) showed apoptosis (cell death) and synergistic anti-proliferative (suppression of cell growth) effects on human fibroid cells. Dr. Ayman Al-Hendy, M.D., Ph.D., Chair of Altin Biosciences’ Medical Advisory Board, and Vice Chair for Research, Department of Obstetrics and Gynecology at University of Chicago, states: “Altin's drug candidate is a significant advancement to offer fibroid patients non-hormonal treatment options that go beyond merely addressing symptoms, offering a paradigm shift in fibroid treatment. Our study shows these natural compounds may provide a safe and cost-effective alternative to current hormonal fibroid therapies ." “Naturally occurring plant-based chemicals, like the potential drug candidate from Altin Biosciences, Crila + EGCG, is a promising drug candidate for evaluation through clinical trials for its safety and efficacy in treating gynecological conditions like uterine fibroids. Fibroids cause significant negative impact on the quality of life of women suffering from them. An effective non-hormonal intervention that reduces the fibroid size and associated symptoms would potentially alter fibroid management for millions of women in a positive manner.” Bhuchitra Singh, MD, MPH. Altin’s Chief Medical Officer and Director of Clinical Research, Department of Gynecology and Obstetrics, Division of Reproductive Sciences and Women’s Health Research, Johns Hopkins University School of Medicine. Uterine fibroids impact up to 80% of women, disproportionately impacting women of color.[1] These non-cancerous tumors cause debilitating symptoms and increase the risk of infertility, preterm delivery, post-partum hemorrhage, and anemia. Each year in the US alone, 300,000 elective hysterectomies are due to fibroids.[2] The direct and indirect annual costs associated with fibroids in the United States are $42.2 billion.[3] About Altin Biosciences Altin Biosciences is an impact-focused company in botanical drug development for unmet medical needs. Established in 2022, Altin’s lead drug candidate is backed by over 30 years of research by top scientists collaborating internationally and meets patient and physician preference for non-invasive, non-hormonal treatments that preserve fertility and reduce reliance on hysterectomy. Altin seeks to revolutionize the treatment of uterine fibroids and additional conditions, including menopause, endometriosis and prostate conditions. For more information, please visit altinbiosciences.com or write to info@altinbiosciences.com REFERENCES 1. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512. doi:10.1111/1471-0528.14640 2. Stoelinga B, Huirne J, Heymans MW, Reekers JA, Ankum WM, Hehenkamp WJK. The estimated volume of the fibroid uterus: a comparison of ultrasound and bimanual examination versus volume at MRI or hysterectomy. Eur J Obstet Gynecol Reprod Biol. 2015;184:89-96. doi:10.1016/j.ejogrb.2014.11.011. 3. Hazimeh D, Coco A, Casubhoy I, Segars J, Singh B. The Annual Economic Burden of Uterine Fibroids in the United States (2010 Versus 2022): A Comparative Cost-Analysis. Reprod Sci. 2024 Dec;31(12):3743-3756. doi: 10.1007/s43032-024-01727-0. Epub 2024 Oct 25. PMID: 39455488. Sue McKinney Altin Biosciences Corporation +1 252-452-6245 suemckinney@AltinBiosciences.com Visit us on social media: LinkedIn Bluesky YouTube Dr. Ayman Al-Hendy and Altin Biosciences CEO Sue McKinney discuss the fertility-friendly potential for Altin's non-hormonal uterine fibroid drug candidate. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Fast Track

100 Deals associated with (-)-Epigallocatechin Gallate

External Link

KEGG	Wiki	ATC	Drug Bank
-	(-)-Epigallocatechin Gallate	-	DB12116

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Radiodermatitis	Phase 3	Mexico	Universidad de Guanajuato	01 Sep 2025
Muscular Dystrophy, Duchenne	Phase 3	Germany	Charité - Universitätsmedizin Berlin	30 Dec 2010
Alzheimer Disease	Phase 3	Germany	Charité - Universitätsmedizin Berlin	01 Oct 2009
Brain atrophy	Phase 3	Germany	-	01 May 2009
Multiple Sclerosis, Chronic Progressive	Phase 3	Germany	-	01 May 2009
Hepatocellular Carcinoma	Phase 2	United States	The University of Texas Southwestern Medical Center	01 Sep 2024
Liver Cirrhosis	Phase 2	United States	The University of Texas Southwestern Medical Center	01 Sep 2024
Huntington Disease	Phase 2	Germany	Charité - Universitätsmedizin Berlin	01 Sep 2011
Multiple Sclerosis, Relapsing-Remitting	Phase 2	Germany	Charité - Universitätsmedizin Berlin	01 Sep 2007
Idiopathic Pulmonary Fibrosis	Phase 1	United States	The University of California, San Francisco	24 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05758571 (Pubmed) Manual	Phase 1/2	Pneumonia	54	epigallocatechin-3-gallate7umol/L	mfpyxbvfbq(jhjirpbcfw) = mkobgqdeis ywjntfueuq (gzesttqehb ) View more	Positive	17 Apr 2024
NCT02008721 (PROMESA, CTgov)	Phase 3	Multiple System Atrophy	92	EGCG as putative neuroprotective agent (EGCG as Putative Neuroprotective Agent)	cioegrhkhm(adnzuwoxnt) = yplxbfkpmk uqrsxltbic (bihawlzbnc, 1.01) View more	-	12 Mar 2024
				Placebo (Placebo)	cioegrhkhm(adnzuwoxnt) = dbxulawmff uqrsxltbic (bihawlzbnc, 0.99) View more
NCT02580279 (phase II clinical study, Pubmed \| Int J Radiat Oncol Biol Phys)	Phase 2	Breast Cancer	-	EGCG and radiotherapy	fvhyeeavhb(kwcagwjaks) = qjgjhipzej hfktkxweso (mkufrlevhu ) View more	Positive	01 Oct 2023
				Control group (radiotherapy only)	fvhyeeavhb(kwcagwjaks) = hnrymbzjlv hfktkxweso (mkufrlevhu ) View more
NCT02580279 (phase II clinical study, ASTRO2023 \| Pubmed)	Phase 2	Breast Cancer	-	EGCG and radiotherapy	fqjydlgaqd(ewykrvxznn) = ngvvrflehd vrojtujskb (hziumvycpb ) View more	Positive	01 Oct 2023
				Control group (radiotherapy only)	fqjydlgaqd(ewykrvxznn) = ewdizhcazb vrojtujskb (hziumvycpb ) View more
ChiCTR2100053703 (ASTRO2023)	Phase 2	Pelvic Neoplasms Adjuvant	37	EGCG 400mg	tuxyucwyak(acfkyhoxpp) = qbmylraayp qnxffwddaj (qmbzapykfb ) View more	Positive	01 Oct 2023
NCT02580279 (Pubmed)	Phase 1	Neoplasms \| Dermatitis	19	EGCG solution	jmaohtzksu(khfadguzet) = significant relief can be observed in burning sensation after 15 days of EGCG treatment rjoizzywom (gkfecusvmb ) View more	-	24 Aug 2023
NCT03928847 (CTgov)	Early Phase 1	Idiopathic Pulmonary Fibrosis	35	Epigallocatechin-3-gallate (EGCG) (EGCG PK in Healthy Volunteers 450 mg)	gwjtgfxuep(vhsbnmpami) = cevkxvfcao upcgsiqoij (xduxfidfql, NA) View more	-	22 Dec 2022
				Epigallocatechin-3-gallate (EGCG) (EGCG PK in Healthy Volunteers 750 mg)	gwjtgfxuep(vhsbnmpami) = ryrwjbctfo upcgsiqoij (xduxfidfql, NA) View more
NCT00799890 (SUPREMES, Pubmed \| Front Neurol)	Phase 2/3	Multiple Sclerosis, Chronic Progressive	31	EGCG treated	qbveekpjqg(sbdfvhackj) = gdhsbhpbtt szjcvcdvkx (iqdijstsjt, [0.67]) View more	-	01 Jan 2021
				Placebo	qbveekpjqg(sbdfvhackj) = ovcfdbfkql szjcvcdvkx (iqdijstsjt, [0.47]) View more
NCT01928485 (CTgov)	Phase 2	Prostatic Cancer	6	active surveillance (Arm A (Active Surveillance))	sevwuhddah(vyldbqyfmt) = eksqeapkqa oiglflexov (fvgsqyolvq, 2.29) View more	-	03 Mar 2020
				laboratory biomarker analysis+Sunphenon (Arm B (Sunphenon))	sevwuhddah(vyldbqyfmt) = nxdsjabwjh oiglflexov (fvgsqyolvq, NA) View more
NCT02008721 (PROMESA, MDS2018)	Phase 2/3	Multiple System Atrophy	127	EGCG	dfqtiicumw(oektgvhqwb) = Individual cases of hepatotoxicity in the EGCG group show that the limit of maximal tolerable doses was reached ormrcutjma (mjddtyygxw ) View more	Negative	05 Oct 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis